Lilly: Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has shown the ability in preclinical studies to cross the blood-brain barrier.
Read full article »
Lilly is a Massachusetts-based pharmaceutical company that develops, produces and markets pharmaceutical products for healthcare professionals, patients and consumers.
Read more